A new treatment for arthritis involves a medication called baricitinib (Olumiant).
How does baricitinib work?
Baricitinib is a targeted disease-modifying antirheumatic drug (DMARD). It works by blocking Janus kinase (JAK), which are enzymes that enable inflammatory signals inside cells. By blocking these enzymes, the medication reduces inflammation and helps manage arthritis symptoms.
Key Features of Baricitinib:
- Type of Medication: DMARD (Disease-Modifying Antirheumatic Drug)
- Method of Administration: Oral pill taken once daily
- Target: Janus kinase (JAK) enzymes
- Action: Reduces inflammation by blocking JAK enzymes
What does this mean for arthritis patients?
- Convenience: Being an oral medication taken once a day, it is a convenient alternative to some other arthritis treatments.
- Targeted Approach: As a targeted DMARD, it specifically works on the inflammatory pathways, potentially providing more effective relief.
- FDA Approval: With FDA approval, patients can have confidence in the medication's safety and effectiveness.
Understanding DMARDs
Disease-modifying antirheumatic drugs (DMARDs) are a class of medications that aim to slow down the progression of arthritis and help prevent joint damage. These drugs are different from pain relievers or anti-inflammatories, which only treat the symptoms of arthritis, as DMARDs work on the underlying disease process.
Additional Notes
Here is a summary table:
| Treatment | Type | Administration | Mechanism of Action |
|---|---|---|---|
| Baricitinib (Olumiant) | Targeted DMARD | Oral (once daily) | Blocks Janus kinase (JAK) |
